Adenoviral-Based Cancer Vaccines Promote Anti-PD-1 Treatment Efficacy

Area of Science:

• Oncology
• Immunotherapy
• Vaccinology

Background:

• Immune checkpoint inhibitors like anti-PD-1 therapy have revolutionized cancer treatment.
• However, many patients do not respond to or develop resistance against anti-PD-1 therapy.
• Novel strategies are needed to enhance anti-PD-1 efficacy.

Purpose of the Study:

• To investigate if a gorilla adenovirus vaccine targeting tumor neoepitopes can enhance the activity of anti-PD-1 therapy.
• To evaluate the potential of this combination strategy in preclinical cancer models.

Main Methods:

• Development of a gorilla adenovirus vector vaccine encoding specific tumor neoepitopes.
• Administration of the vaccine in combination with anti-PD-1 antibodies in relevant cancer models.
• Assessment of tumor growth, immune cell infiltration, and overall survival.

Main Results:

• The combination of the neoepitope vaccine and anti-PD-1 therapy resulted in significant tumor regression.
• Enhanced infiltration of cytotoxic T lymphocytes into the tumor microenvironment was observed.
• Improved survival rates were demonstrated in the combination treatment group compared to monotherapy.

Conclusions:

• Targeting tumor neoepitopes with a gorilla adenovirus vaccine can synergize with anti-PD-1 therapy.
• This combination strategy represents a promising approach to overcome resistance and improve responses to immune checkpoint blockade.
• Further clinical investigation is warranted to translate these findings into patient benefit.